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Background: Phenethyl isothiocyanate (PEITC), present naturally in cruciferous vegetables, is a chemopreventive
agent. It blocks initiation and post-initiation progression of carcinogenesis. Mechanism study in human prostate
cancer cells revealed that PEITC is a dual inhibitor of aberrant DNA hypermethylation and histone deacetylases,
reactivating silenced genes and regulating the androgen-mediated growth of tumor cells. The identity of the
cellular organelle that initially interacts with PEITC has not been fully described.
Methods: Human prostate cancer LNCaP cells were exposed to PEITC and the effects on cellular fine structure
examined by transmission electron microscopic studies. Alteration of mitochondrial membrane potential and
cytochrome c release were evaluated as early events of apoptosis, and the TUNEL method for quantifying apoptotic
cells. Mitochondria were isolated for determining their protein expression.
Results: Ultrastructural analyses have revealed condensed mitochondria and a perturbed mitochondrial cristae
structure, which assumed a rounded and dilated shape within 4-hours of PEITC contact, and became more
pronounced with longer PEITC exposure. They presented as the most prominent intracellular alterations in the
early hours. Mitochondria structure alterations were demonstrated, for the first time, with the isothiocyanates. An
increase in the number of smooth endoplasmic reticulum and vacuoles were also noted that is consistent with
the presence of autophagy. Early events of apoptosis were detected, with cytochrome c released along with the
appearance of mitochondrial alteration. Mitochondrial membrane potential was disrupted within 18 hours of PEITC
exposure, preceding the appearance of apoptotic cells with DNA strand breaks. In parallel, the expression of the
mitochondrial class III ß-tubulin in the outer membrane, which associates with the permeability transition pore,
was significantly reduced as examined with isolated mitochondria.
Conclusion: Mitochondria may represent the organelle target of the isothiocyanates, indicating that the
isothiocyanates may be mitochondria-interacting agents to inhibit carcinogenesis.
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Among the well-documented chemopreventive agents are
the isothiocyanates, which occur naturally in a wide var-
iety of cruciferous vegetables including broccoli, cabbages,
kale, cauliflower, watercress, and mustard [1]. When the
vegetables are cut or masticated, the enzyme myrosinase
is released to hydrolyze glucosinolates, which yield isothio-
cyanates [2]. Phenethyl isothiocyanate (PEITC) is derived
from the hydrolysis of the glucosinolate gluconasturtin,
which is found in high amounts in watercress [3,4]. In the
studies of prostate cancer, PEITC has been demonstrated
as a dual inhibitor of DNA hypermethylation and histone
deacetylases, reactivating silenced genes including the
π-class glutathione S-transferase which is inactivated by
aberrant DNA methylation in the vast majority of clinical
prostate tumors [5]. PEITC and its major metabolite have
been demonstrated to inhibit post-initiation progression
of carcinogenesis, including the induction of autophagy,
apoptosis and down regulation of the androgen receptor
thus reducing its growth stimulation on prostate tumor
cells [6-8]. Some isothiocyanates, including PEITC, bind
covalently to cysteines in tubulin as a molecular target,
which may mediate microtubule disruption and blocking
mitosis [9]. The identity of the cellular organelle as the tar-
get in the initial interaction with PEITC, have not been
fully described.
Mitochondrial and ribosomal dysfunctions have been
implicated in cancer [10-13]. The implication includes
an impaired respiratory capacity with increased utili-
zation of glucose, which is considered as a hallmark of
cancer [14,15]. This may in part be related to the structure
of mitochondria, such as the surface area of the inner
membrane and number of cristae, which are correlated
with the aberrant activities of metabolic enzymes in-
cluding the oxidative phosphorylation and cytochrome
c oxidase [16-19]. Aberration of mitochondria-mediated
apoptosis in cancer cells has been described. An ex-
ample is the mitochondrial membrane potential that is
related to apoptosis initiation is known to be higher in
cancer than in normal cells [20,21]. Novel agents target-
ing mitochondria and their pathways in malignant cells
are being explored [22-26].
The structure of mitochondria consists of an outer
membrane wall, and the internal matrix space is parti-
tioned with multiple cristae which are compartments
wrapped by an inner membrane. There are multiple
protein complexes in the membrane and cristae medi-
ate the mechanisms of cellular energy and cell death.
This presentation describes the identification of the alter-
ations in mitochondrial structure and functions mediated
by PEITC through ultrastructural and biochemical ana-
lyses. Mitochondria may represent an early organelle
target in the interaction with isothiocyanates to inhibit
carcinogenesis.Results
Mitochondrial structure alteration by an isothiocyanate
A human prostate cancer cell line LNCaP was chosen
for examining the effects of PEITC on cellular organelles
since its cellular growth dependents on androgen, and the
inhibitory effects of the PEITC has been demonstrated. To
evaluate the early effects of PEITC on the fine structure of
prostate cancer cells, untreated LNCaP cells and those
exposed to 8 μM PEITC for 4–18 hours were prepared for
transmission electron microscopic examination. In com-
parison to the untreated cells (Figure 1A and A’), the main
change in the PEITC-exposed cells was that they exhibited
a perturbed mitochondrial cristae structure and con-
densed mitochondria. The cristae adopted a rounded and
dilated shape, which was observed after 4 hours of PEITC
exposure (Figure 1B and B’), and became progressively
more pronounced at 18 hours of treatment (Figure 1C
and C’). The condensed mitochondria appeared as dense
bodies with a dark matrix and translucent cristae, which
were present after 4 hour (Figure 1B and B’) and 18 hour
PEITC treatment (Figure 1C and C’). At 4 hours the
PEITC-exposed cells also showed more smooth endoplas-
mic reticulum and vacuoles in the cells (Figure 1B’ and C’)
as compared to the control. The vacuoles with larger sizes
were more pronounced after 18 hours. There was no ob-
servable difference in the nuclei ultrastructure between
control and the treated cells. Both of them displayed abun-
dant euchromatin without much heterochromatin. The
results have indicated that the mitochondria were the or-
ganelle with the most prominent alterations at early hours
upon interacting with PEITC. Alteration of mitochondria
structure including cristae remodeling occur during the
early stages of apoptosis [27,28]. Events of apoptosis were
subsequently examined during the early hour of inter-
action with PEITC.
Release of cytochrome c
We next examined the relation of the altered mitochon-
drial structure with cytochrome c release, which is known
as an early event of apoptosis. The level of cytochrome c
in mitochondria of LNCaP cells were determined after
exposure for 4 or 18 hours to 8 μM PEITC, or to a vehicle
control employing a Millipore cytochrome c assay kit. The
mitochondria was permeabilized allowing a FITC-fluo
rescence labeled anti-cytochrome c antibody to react with
cytochrome c in mitochondria, and the fluorescence mea-
sured by flow cytometry. Viable cells demonstrate a higher
level of cytochrome c staining in mitochondria, while
apoptotic cells which have their cytochrome c released
from mitochondria to the cytoplasm, have reduced
fluorescent staining in mitochondria. The fluorescence
level of cytochrome c in mitochondria of untreated
LNCaP cells were compared to LNCaP cells exposed to
PEITC. Figure 2A shows that both 4- and 18-hour
Figure 1 Alteration of mitochondria structure by PEITC. Alteration of cellular fine structure in human prostate cancer cells LNCaP exposed to
PEITC. LNCaP cells without or with the exposure to PEITC at 8 μM were examined by transmission electron microscopy at 4 and 18 hours. Frame
A and A’ show the control cells without the PEITC. Frames B-B’ and C-C’ depicted respectively the PEITC-exposed cells for 4 and 18 hours. Mit:
mitochondria; G: Golgi; Nu: nucleus; RER: rough endoplamic reticulum; SER: smooth endoplasmic reticulum; Cr: cristae; and Vac: vacuoles. Bar in
A = 0.5 μm, valid for B and C. Bar in A’ = 0.5 μm, valid for B’ and C’.
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c level than the untreated cells, with the 4 hour-treatment
level lower than the 18 hour-treatment. The cytochrome c
level in mitochondria, after 4-hour PEITC treatment, was
approximately 16.6% of the untreated cell level, while the
18 hours was approximately 47.6% of the untreated cells.
As the cytochrome c in mitochondria at 4 hour was less
than that of the 18 hour, they indicate that more cyto-
chrome c in mitochondria was released at 4 hour than
18 hour.Class III ß–tubulin expression
The mitochondrial class III β-tubulin associates with the
voltage-dependent anion channel which is part of the
multi-protein permeability transition pore [29]. The ex-
pression of the class III ß-tubulin was examined during
cytochrome c release, using isolated mitochondria, from
cells with or without exposed to 8 μM PEITC for 18 hours.
Western blot in Figure 2B depicts that the levels of the
class III ß-tubulin in PEITC-exposed mitochondria was re-
duced approximately 74%, as compared to that without
PEITC. The results have indicated that the PEITC treat-
ment down-regulated the expression of the tubulin in the
multi-protein permeability transition pore, suggesting a
possible association with the alteration of the mitochon-
dria structure and functions.Mitochondrial membrane potential disruption
A disruption of mitochondrial membrane potential has
described as an early event of the apoptosis process [30].
Mitochondrial membrane potential was examined by
staining with a dye, JC-1, which forms a color aggregate
depending on the membrane potential, and the fluores-
cence measured by a flow cytometric method. As a posi-
tive control, the LNCaP cells were exposed to an agent
CCCP that is known to disrupt membrane potential,
which resulted in a shift from red fluorescence of un-
treated cells to green florescence. LNCaP cells were
treated with 4 or 8 μM PEITC for 4–18 hours, and a
concentration-related shift from red to green fluores-
cence was observed. Figure 3 shows representative ana-
lyses after 18 hours of treatment. Cells exposed to 4 μM
PEITC have an increase of green fluorescence from
14.6% of untreated cells, to 61.1% of treated cells, repre-
senting approximately four fold increase. When cells
were exposed to 8 μM PEITC, the cells with green fluor-
escence increased from 14.6% of untreated cells to
74.2%, indicating a fivefold enhancement. The results
have indicated that the mitochondrial membrane poten-
tial was disrupted by PEITC.
Previous reports from us and others have described
that PEITC induces growth arrest and apoptosis in hu-
man prostate cancer cells, including the LNCaP cell line
[5-7,31]. The apoptosis events of the LNCaP cells were
Figure 2 Decrease of mitochondrial cytochrome c level and
class III ß-tubulin by PEITC. Graph 2A shows mitochondrial
cytochrome c levels after the LNCaP cells exposed to 8 μM of PEITC
for 4 or 18 hours. □ indicates the background FITC-fluorescence
level, in arbitrary log unit, which were from cells stained with an
isotype control instead of the cytochrome c antibody. ▒ indicates
the cytochrome c level in mitochondria of untreated LNCaP cells,
which was a mean of the LNCaP cells cultured for 4 and 18 hours.
▧ indicates a reduced FITC-cytochrome c level in mitochondria after
the cells were exposed to 8 μM PEITC for 4 hr, and ▤ indicates the
cytochrome c level at 18 hr. Vertical bars indicate the ranges of the
three highest peaks of fluorescence obtained in each experimental
condition. Western blot in Figure 2B shows the down-regulation of
the mitochondrial class III ß-tubulin protein expression in the isolated
mitochondria preparation from the LNCaP cells, which were treated
with 8 μM PEITC for 18 hours. The mitochondria preparation isolated
from untreated LNCaP was used as a control for comparison. The levels
of ß-actin were assayed as a loading control.
Figure 3 Disruption of mitochondrial membrane potential. The
LNCaP cells were incubated without or with 4 μM or 8 μM of PEITC
for 18 hrs. The cells were then stained with JC-1 dye to measure
the membrane potential with a flow cytometric method. Separate
control cell cultures were stained with CCCP, a reagent known to
disrupt the mitochondrial membrane potential that shifts the untreated
cells with red fluorescence to the potential disrupted cells with green
florescence. The figure shows that after PEITC exposure there was a
concentration-related shift of the LNCaP cells with the red fluorescence
to green color as that seen with the control CCCP for membrane
potential disruption. (□) indicates the percent LNCaP cells with red
fluorescence, and (▐ ) indicates the percent of LNCaP cells with the
green fluorescence. The vertical bars indicate the means and ranges of
two independent experiments.
Table 1 Percent apoptotic cells of PEITC-exposed prostate
cancer LNCaP cells1
PEITC (μM) Exposure time (h)
4 18 48
0 1.3 ± 1.5 1.6 ± 2.1 3 ± 2
5 1.3 ± 1.5 6.5 ± 3.8 24 ± 7.2
8 2 ± 1.7 7.7 ± 2.7 32.3 ± 11.2
1Apoptotic cells were determined by the TUNEL method. Numbers ± SE were
obtained from separate five experiments.
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with PEITC, along with the appearance of the alteration
of mitochondrial structure. Table 1 describes that apop-
totic cells with DNA strand breaks, as enumerated by the
TUNEL assay, were mainly present after 18–48 hours of
PEITC exposure. The levels of apoptotic cells prior to
18 hours with 8 μM PEITC were close to the background
level, the same as the electron microscopic examination
which did not observe many apoptotic cells, during the
same time period. Since the mitochondrial structure alter-
ation, membrane potential disruption, and cytochrome c
release were observed within 18 hours of PEITC exposure,
the results indicated that apoptotic cells became detect-
able after these early events of apoptosis.Discussion
Ultrastructural analyses have revealed that PEITC affects
mitochondria. The cristae developed a rounded and di-
lated shape within four hours, along with condensed
mitochondria representing the most prominent intra-
cellular change in the early hours. It is the first time to
demonstrate an altered mitochondrial structure by an
isothiocyanate. PEITC and other isothiocyanate have
been described to mediate growth arrest and apoptosis
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represent the early organelle target of the isothiocya-
nates to inhibit carcinogenesis.
Parallel to the alteration of mitochondria structure,
early events of apoptosis including mitochondrial mem-
brane potential disruption and cytochrome c release
were demonstrated. In the subsequent hours, the pres-
ence of apoptotic cells with DNA strand breaks could
then be detected, which confirms the previously reports
of the induction of apoptosis by PEITC [7,31]. Altered
mitochondrial structure, such as condensed mitochon-
dria has functional correlate. As it was first characterized
in liver mitochondria by electron microscopic examin-
ation [32], condensed mitochondria indicate an effort to
increase ATP production [33,34]. Our finding of the
PEITC-mediated mitochondrial structural alteration and
its relation with apoptosis is in line with earlier report
that altered morphology and structure of mitochondria
were present during early stages of apoptsis [28].
An alteration in cristae shape and surface area signifies
changes of protein functions in the cristae compartment,
as well as those occurring in the mitochondrial mem-
branes. The changes seen in membrane potential and
the class III ß-tubulin may represent, in part, the alter-
ations by PEITC. This is because the inner and outer
membranes have other functions. For instance, the inner
membrane contains the electron transport-proteins that
move metabolites across the membrane, while the outer
membrane contains the permeability transition pore,
and the voltage-dependent anion channel for molecules
traversing through mitochondria. Isothiocyanates might
affect functions in metabolism and energy that could be
pivotal for tumor cell survival, which are currently being
investigated.
Down-regulation of the mitochondria class III ß-tubu-
lin, which locates in the outer membrane, has indicated
that PEITC may affect membrane proteins and their
functions, and may be involved in the alteration of mito-
chondria structure. De Gendt et al. [35] reported that
the class III ß-tubulin gene is regulated by androgen in
mouse and rat sertoli cells, describing it as a direct target
of the androgen receptor. Since PEITC is known to reduce
the androgen receptor in the LNCaP cells [8], the down-
regulation of the class III ß-tubulin could be the result of
reduced androgen receptor. Another possibility for the
down-regulation of the class III β-tubulin is that tubulin
is the molecular target of PEITC [9], and a reduced β-
tubulin could be the result of the binding of PEITC to the
β-tubulin which is currently being investigated.
Transmission electron microscopy has revealed an
increase of the smooth endoplasmic reticulum by PEITC.
They are usually prominent in cells specializing in lipid
metabolism. For example, hepatocytes have abundant
smooth endoplasmic reticulum as they produce lipoproteinsparticles, and they contain phase 1 enzymes such as
Cytochrome P450s to process lipid soluble chemicals
and other harmful compounds produced by metabol-
ism. Whether the increase of smooth endoplasmic
reticulum associated with the detoxifying activity of
PEITC [2,4], and whether PEITC is being metabolized
there remains to be investigated. Electron microscopy also
detected an increase of vacuoles upon PEITC treatment.
They could be due to autophagy which precedes apop-
tosis. This interpretation is in line with the report of
Bommareddy et al. [31] that autophagy could be in-
duced by PEITC in human prostate cancer PC-3 cells.
Conclusion
Mitochondria have been determined as the primary intra-
cellular organelle of the phenethyl isothiocyanate (PEITC)
during the early interaction between the isothiocyanate
and the prostate cancer cells. The interaction caused sig-
nificant structure alteration of mitochondria including per-
turbed cristae structure with rounded and dilated shape,
condensed mitochondria, and a changed expression of
mitochondrial class III ß-tubulin which associates with the
permeability transition pore. The alteration of mitochon-
dria structure may be involved in the early events of the
mitochondrial pathway of apoptosis, indicating the isothio-
cyanates may be mitochondria-interacting agents.
Methods
Cell cultures and reagents
Human prostate cancer cell line LNCaP was purchased
from ATCC and characterized there for fewer than
6 months before experimentation. Cells were seeded at
1.5 × 105 cells/ml with RPMI-1640 medium, 10% FCS,
and antibiotics. Some cultures were exposed for vari-
ous time period to 8 μM phenethyl isothiocyanate
(PEITC), which was prepared in phosphate buffer and
DMSO [5]. A DMSO vehicle control was used in every
experiment. PEITC was purchased from LKT Labs
with 98% purity. Apoptotic cells were determined by
the presence of DNA strand breaks measured by ter-
minal deoxynucleotidyl transferase-mediated biotinyl-
ated UTP nick end-labeling (TUNEL) [7].
Transmission electron microscopy
LNCaP cells were fixed with 2% glutaraldehyde in sodium
cacodylate buffer and embedded in Epon resin. Ultrathin
sections were cut, collected on 200 mesh copper grids and
stained with uranyl acetate and lead citrate. They were ex-
amined in the Tecnai G2 Biotwin at 80 kV (FEI). Images
were collected with an AMT 2 K digital camera system.
Mitochondrial membrane potential
Mitochondrial membrane potential was measured with
a potential sensitive dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-
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method described elsewhere [36]. In healthy cells, JC-1
stains the mitochondria red due to the formation of dye
aggregates. When the membrane potential is disrupted,
the JC-1 dye accumulates in cytoplasm as monomeric
form, which shows green fluorescence. The LNCaP cells
with or without PEITC exposures were incubated with
JC-1 at 10 μg/ml. Cells were washed and the florescence
measured with a Becton-Dickinson FACScan flow cyt-
ometer. A reagent carbonyl cyanide 4-(trifuoromethoxy)
phenyhydrazone (CCCP) that mediates the collapse of
membrane potential was added to cells at 50 μM, as a
positive control [36].
Cytochrome c release
The amount of cytochrome c released from mitochondria
was evaluated in reference to the level of cytochrome c
remained in mitochondria in the experiments. Mitochon-
drial cytochrome c was determined employing a Millipore’s
FlowCellect cytochrome c kit according to manufacturer’s
direction. Essentially, cells were incubated for 10 min with
a permeabilization solution to achieve selective permea-
bilization of mitochondria. Cells were fixed, incubated with
a blocking buffer, and stained with a FITC-labeled antibody
for cytochrome c present in mitochondria. An isotype
control immunoglobulin was used in place of the anti-
cytochrome c antibody as a background. The fluores-
cence intensity was measured by a BD FACSCalibur
flow cytometer.
Mitochondria isolation
Mitochondria from LNCaP cells were isolated with a
mitochondrial isolation kit (Thermo Scientific) following
the manufacturer’s instructions. Essentially, each pellet
of 2 × 107 cells was lysed and centrifuged at 12,000 × g to
separate the cytosol fraction from the mitochondria. Pro-
tein lysates were prepared from the isolated mitochondrial
pellets. Western blotting was performed with 10% SDS-
PAGE [8]. A polyclonal antibody against the mitochon-
drial class III ß-tubulin (Covance Research Products) was
used for immunoblotting [37]. To ascertain the antibody
reacted with the class III ß-tubulin from mitochondria, a
purified porin preparation from the mitochondrial mem-
brane which contains class III ß-tubulin (Covance) was
used in immunoblotting as a positive control. An antibody
against ß-actin was used as a loading control. The percent
change of the expression of class III β-tubulin in cells,
without or with PEITC treatment, was calculated based on
the densities of the tubulin immune complexes from each
cell preparations.
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